Insulet 10-Q Details Q3 EPS of $2.03, $211.7M Free Cash Flow and New $1B Buyback
PODD sits 31% above its 52-week low of $126.4.
Summary
Insulet's Q3 10-Q confirms $842.0M revenue, $141.1M net income ($2.03 EPS) and 75.1% gross margin, with $211.7M of nine-month free cash flow and a newly authorized $1 billion buyback through 2028.
Key Events · Earnings and Guidance · PODD
-
Q3 Revenue Up 19.2% to $842.0M
Total revenue rose to $842.0M from $706.3M, with international up 31.7% to $266.2M and U.S. Omnipod up 14.7% to $570.4M.
-
Net Income $141.1M, EPS $2.03
Gross margin expanded 280 bps to 75.1%, helped by a 90 bp benefit from a $7.0M warranty accrual reduction tied to the device corrections.
-
Free Cash Flow Falls to $211.7M
Nine-month operating cash flow was $325.7M against $113.9M of capex; working capital absorbed $177.3M, driven by a $179.6M receivables build and $103.0M inventory increase.
-
$1B Buyback Authorized in October
The board authorized $1 billion of repurchases through December 31, 2028, with about $400M expected in 2026; $115.4M remained on the prior program at September 30.
Analysis · PODD · Industrial Applications And Services
The 10-Q puts full numbers behind the Q3 beat already reported this morning: net income of $141.1M ($2.03 diluted EPS) on $842.0M revenue, with gross margin up 280 bps to 75.1%. What the 8-K did not carry is the cash story — nine-month operating cash flow of $325.7M and free cash flow of $211.7M, down $117.8M year over year as receivables and inventory absorbed $282.6M of working capital. The filing also formalizes the October board authorization of a $1 billion buyback through 2028, with roughly $400M expected to be spent in 2026, which is real support for the share count after the 1.25M shares repurchased in the first nine months. Offsetting that, the two voluntary device corrections carry an estimated ~$50M total cost, and the EOFlow trade-secret award is now gone after the Federal Circuit reversal and the October 19 denial of rehearing — no charge was ever booked, so no P&L hit, but the injunction leverage is gone too.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PODD was trading at $165.02 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $11.4B. The 52-week trading range was $126.40 to $354.88. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.